The current state of the pharmaceutical market for drugs used in oncological diseases in the Republic of Kazakhstan

Oncological diseases remain one of the key medical and social problems in the Republic of Kazakhstan, forming a significant burden on the health care system and the mechanism of drug provision. The purpose of the study was a comprehensive assessment of the current state of the pharmaceutical market of antitumor drugs of the Republic of Kazakhstan in the context of the implementation of the Comprehensive Plan for 2023-2027 with an emphasis on the regulatory environment, assortment structure, sources of supply of these drugs and pharmacoeconomic characteristics of therapy. This study utilized structural, comparative marketing and pharmacoeconomic analysis methods, using data from the State Register of Medicines, official statistics from the Ministry of Health of the Republic of Kazakhstan, and information on actual procurement volumes of oncology drugs in 2025 (as of October). An analysis of the product range by Anatomical Therapeutic Chemical (ATC) classification, dosage forms, and trade names was conducted, the role of orphan drugs was assessed, and procurement leaders were identified. The average cost per package and per treatment course for key anticancer drugs was calculated based on instructions for medical use and standard clinical treatment regimens. The study results showed that the pharmaceutical market for oncology drugs in Kazakhstan is characterized by a high concentration of costs on a limited list of targeted and biological drugs, while imports predominate. A significant pharmacoeconomic differentiation was identified between classic cytostatics and innovative drugs, which is of significant importance for planning public funding and optimizing drug provision for cancer patients.